The adverse effects of palmitate were counteracted by rosiglitazone at GPR40, suggesting that thiazolidinediones are beneficial for β-cell function in hyperlipidemic type 2 diabetes. This evidence concerns the gene FFAR1 and type 2 diabetes mellitus.